soul trial oral semaglutide cardiovascular outcomes results 2025 nejm Heart disease is the #1 cause of death in type 2 diabetes — and for the first time, an GLP-1 drug has been The SOUL Study - by
Pay in 4 interest-free payments of $6.50 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
















:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)








